Toggle Navigation
Each
Pod
Each
Pod
Podcasts
Episodes
Genres
Login
Oncology Times - OncTimes Talk
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy
Author
Oncology Times
Published
Tue 18 Jun 2024
Episode Link
https://traffic.libsyn.com/secure/otbroadcastsarchives/OT_POD_EP89_061724.mp3.mp3
Share to:
